Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors

NCT06241456 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT06241456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06241456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
January 5, 2024
Completion date
May 1, 2044
Enrollment
351 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor